Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 5/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DNM1L | O00429 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1045388 | 0.87 | ITGB3 (0.39) | USP30PIM1PIM3PIM2CNR1 | |
| SCHEMBL1044679 | 0.84 | CNR1 (0.40) | USP30PIM1PIM3PIM2CNR1 | |
| SCHEMBL1044681 | 0.84 | ALDH1A1 (0.49) | KMT2ASMN1; SMN2 | |
| SCHEMBL6527833 | 0.83 | KDM4E (0.43) | USP30CNR1PPARGKMT2ANAMPT | |
| SCHEMBL15313014 | 0.83 | PIM1 (0.37) | PIM1PIM3PIM2SMN1; SMN2DNM1L | |
| SCHEMBL14359813 | 0.81 | HDAC1 (0.43) | PIM1PIM3PIM2HDAC6HDAC4 | |
| SCHEMBL1042793 | 0.80 | ALDH1A1 (0.49) | KMT2ASMN1; SMN2 | |
| SCHEMBL2952296 | 0.78 | CASP8 (0.42) | — | |
| SCHEMBL1045160 | 0.77 | HTR2C (0.44) | KMT2ASMN1; SMN2 | |
| SCHEMBL1043029 | 0.76 | USP5 (0.49) | KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546575-B2 | NIP thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydroge-nase-1 | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | claimed |
| EP-2271405-B1 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2013-07-24 | — | — | EP | claimed |
| US-20110060007-A1 | Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 | Merck Patent Gesellschaft Mit Beschrankter Haftling (DE) | 2011-03-10 | — | — | US | claimed |
| WO-2009135581-A9 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2010-11-11 | — | — | WO | claimed |
| WO-2009135581-A2 | NOVEL NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2009-11-12 | — | — | WO | claimed |
| US-8546575-B2 | NIP thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydroge-nase-1 | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| EP-2271405-B1 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2013-07-24 | — | — | EP | disclosed |
| US-20110060007-A1 | Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 | Merck Patent Gesellschaft Mit Beschrankter Haftling (DE) | 2011-03-10 | — | — | US | disclosed |
| WO-2009135581-A9 | NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2010-11-11 | — | — | WO | disclosed |
| WO-2009135581-A2 | NOVEL NIP THIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK PATENT GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060007-A1 | Novel NIP Thiazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydroge-Nase-1 | HSD11B1, HSD17B1, HSD11B2 | USP30 2839/4885PIM1 3286/4885PIM3 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.